Novo Nordisk A/S, of Bagsvaerd, Denmark, said the FDA approved Tretton, coagulation Factor XIII A-subunit (recombinant), for use in the routine prevention of bleeding in adults and children who have rare clotting disorder congenital Factor XIII A-subunit deficiency. Tretton has orphan drug designation in that indication.